28,302 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 28,302 shares of the company’s stock, valued at approximately $604,000.

A number of other hedge funds have also recently made changes to their positions in the company. Grove Bank & Trust grew its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Kenvue in the fourth quarter worth $29,000. SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the last quarter. Asset Planning Inc bought a new position in Kenvue in the fourth quarter valued at $42,000. Finally, Clarity Asset Management Inc. purchased a new stake in Kenvue during the fourth quarter valued at about $45,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $23.86 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average price of $23.15 and a 200-day moving average price of $22.58. The company has a market cap of $45.78 billion, a price-to-earnings ratio of 45.02, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Kenvue’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.28 EPS. As a group, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date is Wednesday, May 14th. Kenvue’s payout ratio is 149.09%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KVUE. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective for the company. Citigroup upped their target price on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Finally, UBS Group increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.